9
Participants
Start Date
January 3, 2019
Primary Completion Date
June 27, 2022
Study Completion Date
June 27, 2022
Bemcentinib
200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
Nab-paclitaxel
25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
Gemcitabine
Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
Cisplatin
Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
University of Texas Southwestern Medical Center, Dallas
Collaborators (1)
Triligent International
INDUSTRY
Translational Genomics Research Institute
OTHER
BerGenBio ASA
INDUSTRY
University of Texas Southwestern Medical Center
OTHER